1	Sensitive quantitative and rapid immunochromatographic
2	diagnosis of clinical samples by scanning electron microscopy -
3	preparing for future outbreaks
4	
5	Running title: Immunochromatographic diagnosis of disease by SEM
6	
7	Hideya Kawasaki*ª, Hiromi Suzukiª, Masato Maekawa <sup>b</sup> , Takahiko Hariyama*ª
8	
9	<sup>a</sup> Institute for NanoSuit Research, Preeminent Medical Photonics Education &
10	Research Center, Hamamatsu University School of Medicine, Hamamatsu, Japan
11	<sup>b</sup> Department of Laboratory Medicine, Hamamatsu University School of Medicine,
12	Hamamatsu, Japan
13	
14	* Corresponding authors: Hideya Kawasaki, Takahiko Hariyama
15	Email: gloria@hama-med.ac.jp, hariyama@hama-med.ac.jp
16	ORCID account: 0000-0001-8923-7722, 0000-0001-9623-1011
17	
18	Author Contributions: H.K. designed research; H.K., H.S., performed research;
19	H.K. M.M., analyzed data; and H.K., T.H. wrote the paper.

20	Abbreviations: EM, Electron microscopy; LAMP, loop-mediated isothermal
21	amplification; SEM, scanning electron microscope; GNP, gold nanoparticles;
22	INSM, immunochromatography-NanoSuit® method; PCR, polymerase chain
23	reaction; rRT-PCR, real-time reverse transcription-polymerase chain reaction, IgG,
24	immunoglobulin G; IgM, immunoglobulin M

### 26 Abstract

27 Background: As pathogens such as influenza virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can easily cause pandemics, rapid 28 29 diagnostic tests are crucial for implementing efficient quarantine measures, 30 providing effective treatments to patients, and preventing or containing a pandemic 31 infection. Here, we developed the immunochromatography-NanoSuit<sup>®</sup> method, an 32 improved immunochromatography method combined with a conventional scanning 33 electron microscope (SEM), which enables observation of immunocomplexes labeled with a colloidal metal. 34

Methods and Findings: The detection ability of our method is comparable to that of real-time reverse transcription-polymerase chain reaction and the detection time is approximately 15 min. Our new immunochromatography-NanoSuit<sup>®</sup> method 38 suppresses cellulose deformity and makes it possible to easily focus and acquire 39 high-resolution images of gold/platinum labeled immunocomplexes of viruses such 40 as influenza A, without the need for conductive treatment as with conventional 41 SEM. Electron microscopy (EM)-based diagnosis of influenza A exhibited 94% clinical sensitivity (29/31) (95% confidence interval [95%CI]: 78.58-99.21%) and 42 43 100% clinical specificity (95%CI: 97.80–100%). EM-based diagnosis was significantly more sensitive (71.2%) than macroscopic diagnosis (14.3%), 44 45 especially in the lower influenza A-RNA copy number group. The detection ability of our method is comparable to that of real-time reverse transcription-polymerase 46 47 chain reaction. Conclusions: This simple and highly sensitive quantitative analysis method involving immunochromatography can be utilized to diagnose 48 various infections in humans and livestock, including highly infectious diseases 49 such as COVID-19. 50

51

# 52 Introduction

Infections are major threats to humanity. The novel influenza A (H1N1) pdm09 was declared a pandemic in 2009 [1], and the current 2020 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has had a devastating impact on human health and the world economy. The following factors are crucial for

57 reducing the effects of these infections: 1: delayed invasion of infection into the country because of border measures and guarantine, 2: early containment 58 59 strategies. 3: early diagnosis enabling appropriate treatment, and 4: broad antibody (IgM, IgG) and/or antigen testing against the virus to assess the 60 61 spread of the virus. Therefore, rapid diagnostic tests are crucial for disease 62 prevention, treatment, and pandemic containment [2]. Although real-time reverse 63 transcription-polymerase chain reaction (rRT-PCR) is a sensitive method, it is time-64 consuming, costly, and requires special equipment with professional expertise and high-quality samples. For point-of-care testing, immunochromatography is easier 65 66 to perform and useful for prompt disease detection, but its sensitivity and specificity are lower than those of rRT-PCR. However, improved specificity has been 67 68 achieved by using lateral flow biosensors (LFBs) with micro- and nano-materials 69 [3]. Signal readouts based on color, electrochemical signals, magnetic properties, 70 luminescent, and surface-enhanced Raman spectroscopy have been integrated 71 with LFBs for quantification analyses [3,4]. Nevertheless, these nanoparticle 72 sensing methods are indirect. Direct observation of metal nanoparticles by electron 73 microscopy (EM) for clinical use has not been reported because of the complexity 74 of sample preparation and conventional EM operation. We recently reported a 75 method for evaluating multicellular organisms in high vacuum of an EM by encasing them in a thin, vacuum-proof suit, the 'NanoSuit<sup>®'</sup> [5], which can impart 76

77 conductivity to a wet sample to avoid electron charges. Here, we combined the NanoSuit® 78 method with immunochromatography. The new 79 immunochromatography-NanoSuit<sup>®</sup> method (INSM) suppresses the deformity of 80 the immunochromatography substrate such as cellulose, which causes blurring of 81 particle images, and enables easy focus and acquisition of high-resolution images 82 without the need for additional conductive treatment [6] as with a conventional scanning EM (SEM). In the medical field, using rRT-PCR and INSM as two 83 84 sensitive rapid diagnostic tests will help maintain patient health. INSM also is a highly sensitive diagnostic tool for several pathogenic infections or other diagnoses. 85

86

# 87 Methods

#### 88 Ethical statement

The study was approved by the Hamamatsu University School of Medicine ethical committee (No. 19-134), and all methods were performed following relevant guidelines and regulations.

#### 92 Immunochromatography kit

93 The ImunoAce<sup>®</sup> Flu kit (NP antigen detection), a human influenza commercial
94 diagnosis kit, was purchased from TAUNS Laboratories, Inc. (Shizuoka, Japan).

Au/Pt nanoparticles were utilized to visualize the positive lines. A total of 197
clinical samples from patients suspected to be suffering from influenza were
provided by a general hospital at the Hamamatsu University School of Medicine
for examination using the Flu kit. After macroscopic diagnosis using the Flu kit, the
samples were stored in a biosafety box at room temperature (20-25 °C / 68 - 77 °F).
The IgM detection immunochromatography kit against SARS-CoV-2 was obtained
from Kurabo Industries, Ltd. (Osaka, Japan).

#### 102 One step rRT-PCR for influenza A

103 rRT-PCR for influenza A was performed as described previously using Flu A
104 universal primers [7]. A Ct within 38.0 was considered as positive according to the
105 CDC protocol [8]. The primer/probe set targeted the human RNase P gene and
106 served as an internal control for human nucleic acid as described previously [9].

#### 107 SEM image acquisition

The immunochromatography kit was covered with modified NanoSuit<sup>®</sup> solution
based on previously published components [5] (Nisshin EM Co., Ltd., Tokyo,
Japan), placed first onto the wide stage of the specimen holder, and then placed

in an Lv-SEM (TM4000Plus, Hitachi High-Technologies, Tokyo, Japan). Images
were acquired using backscattered electron detectors with 10 or 15 kV at 30 Pa.

#### 113 Particle counting

In fields containing fewer than 50 particles/field, the particles were counted manually. Otherwise, ImageJ/Fiji software was used for counting. ImageJ/Fiji uses comprehensive particle analysis algorithms that effectively count various particles. Images were then processed and counting was performed according to the protocol [10].

#### 119 **Diagnosis and statistics**

120 The EM diagnosis and criteria for a positive test were defined as follows: particle 121 numbers from 6 fields from the background area and test-line were statistically 122 analyzed using the *t*-test. If there were more than 5 particles in one visual field and 123 a significant difference (P < 0.01) was indicated by the *t*-test, the result was 124 considered as positive. Statistical analysis using the *t*-test was performed in Excel 125 software. Statistical analysis of the assay sensitivity and specificity with a 95% 126 confidence interval (95% CI) was performed using the MedCalc statistical website. The approximate line, correlation coefficient, and null hypothesis were calculated 127 128 with Excel software.

130 **Results** 

131 To investigate the sensitivity and specificity of immunochromatography using the NanoSuit® method, an influenza diagnostic kit (TAUNS Laboratories, Inc.) was 132 133 prepared (Fig. 1A). Two specific antibodies were used: one (anti-mouse IgG or anti-influenza A NP) was immobilized on chromatographic paper, whereas the 134 135 other was labeled with colloidal gold/platinum (100-200 nm in diameter) and infiltrated into the sample pad. The kit was completed by attaching the sample pad 136 137 at the end of the membrane. When the clinical sample in lysis buffer (150  $\mu$ L) was 138 placed on the sample pad, the virus antigen in the sample formed an 139 immunocomplex with the colloidal gold/platinum- labeled antibody, which 140 subsequently formed an immune complex with the antibody immobilized on the membrane, resulting in the generation of colored lines and indicating the presence 141 142 of the antigen of interest in the sample (Fig. 1B top, middle). After the reaction, NanoSuit<sup>®</sup> solution (100 µL) was added upstream of the test-line (Fig. 1B middle), 143 144 forming a thin NanoSuit<sup>®</sup> liquid layer (pale blue) (Fig. 1B bottom). The kit was 145 positioned on the sample stage in the sample chamber of the SEM as close and 146 parallel as possible to the camera (Fig. 1C). The observation position of the test-147 line and background area were determined at fixed distances from the control-line border. The number of Au/Pt particles at the test-line and background area were
counted in 6 fields of view at ×1200 (Fig. 1*D*). Without NanoSuit<sup>®</sup> treatment,
swelling of the cellulose and residual liquid present due to electron beam energy
were observed (Fig. 2*A*). In contrast, following NanoSuit<sup>®</sup> treatment, the cellulose
membrane showed little or no swelling (Fig. 2*B*).

153 The SEM images of the test lines and background were compared. Figure 3A, 154 D show the "macroscopic diagnosis-positive" test-line. Figure 3B, E are images of 155 the "macroscopic diagnosis-negative" and "EM diagnosis-positive" test-line. Figure 3C, F are the images of the background. Au/Pt particles (arrows) of the 156 157 test-line were clearly visualized (Fig. 3A, B, D, E) compared to background areas of the cellulose membrane (Fig. 3C, F). Au/Pt particle counting was performed by 158 159 using ImageJ/Fiji software for macroscopic diagnosis-positive samples. Manual 160 counting was performed for the images of "background" and "macroscopic diagnosis negative and SEM diagnosis-positive" samples as well as "EM-negative" 161 162 samples. Another immunochromatography diagnosis kit for detecting IgM 163 antibodies against SARS-CoV-2 from Kurabo Industries, Ltd. was tested using the NanoSuit<sup>®</sup> method (S1A Fig). The cellulose membrane image without the 164 immunocomplex was clearly visualized after NanoSuit<sup>®</sup> treatment (S1B Fig). 165

Approximately 25-nm countable gold nanoparticles (GNPs) of the control-line were
detected (S1C Fig).

168 Diagnoses based on macroscopic, EM, and rRT-PCR results were compared using the 197 influenza-suspected clinical samples. rRT-PCR for influenza A was 169 170 performed with the same clinical pharyngeal swab samples as used in 171 immunochromatography. To examine the relationship between the influenza copy 172 number and rRT-PCR threshold, serial dilutions were prepared (S2A Fig). A 173 calibration curve (S2B Fig) was drawn to determine the relationship between the 174 copy number and cycle threshold (Ct) (S2C Fig). In our assay system, Ct  $\leq$  38.0 175 was calculated to be  $\geq$  151.4 copies/reaction.

The quantitative relationship between particle counts/fields (log10) and Ct are shown as a scatter diagram. The correlation coefficient of Ct and particle counts/field was -0.803, which was significant (p = 3.79E-08) and the null hypothesis was rejected (**Fig. 4**) (**Supplemental data**).

The EM diagnosis for influenza A showed 94% clinical sensitivity (29/31) (95% confidence interval [95%CI]: 78.58–99.21%) and 100% clinical specificity (95%CI: 97.80–100%) (**Table 1**) (**Supplemental data**), as well as a strong correlation (kappa; 0.99) compared with the results obtained by rRT-PCR (14.0  $\leq$  Ct  $\leq$  38.0) (**Table 2**) (**Supplemental data**). In contrast, standard macroscopic diagnosis showed 77% clinical sensitivity (24/31) (95%CI: 58.90–90.41%) and 100% clinical specificity (95%CI: 97.80–100%) (**Table 1**) (**Supplemental data**), along with a strong correlation (kappa; 0.96) compared with the results obtained by rRT-PCR (14.0  $\leq$  Ct  $\leq$  38.0) (**Table 2**)(**Supplemental data**).

189

# 190 Discussion

191 Rapid diagnostic tests show variable assay performance with sensitivities of 10-192 70% and up to 90% specificity compared to standard rRT-PCR-based assays [11]. 193 Their sensitivity has been improved by employing europium nanoparticles, which 194 show 82.59% sensitivity and 100% specificity for clinically evaluated influenza A 195 (H1N1) [12]. The use of silver amplification immunochromatography in influenza 196 virus detection kits showed 91.2% sensitivity and 95.8% specificity [13]. Moreover, 197 the rapid fluorescent immunochromatographic test employing CdSe/CdS/ZnS 198 guantum dots showed 93.75% clinical sensitivity and 100% clinical specificity [14]. 199 However, the potential toxic effects of cadmium-based quantum dots are 200 controversial [15]. INSM is safe and showed the highest sensitivities (94% clinical 201 sensitivity, 100% clinical specificity) in this study. Generally, overall sensitivity 202 depends on the distribution of each sample's pathogen-copy number in the 203 investigated group. Our study revealed that EM diagnosis was significantly more

204 sensitive (71.2%) than macroscopic diagnosis (14.3%) in the lower copy number 205 group  $(30.0 \le Ct \le 38)$ . The detection ability of our method is comparable to that of 206 rRT-PCR (Fig. 4). Theoretically and practically, our method shows the highest detection performance as an immunochromatographic diagnostic method. More 207 sensitive immunochromatographic products may be developed in future through 208 209 further improvements such as by optimizing the antigen concentration. PCR has recently been used as a main diagnostic tool for SARS-CoV-2. The 210 211 introduction of immunochromatography analysis using the SARS-CoV-2 antigen 212 has greatly changed testing practices. All immunochromatographic-negative 213 SARS-CoV-2-suspected samples are recommended for analysis by PCR. Highly 214 sensitive immunochromatographic tests for infectious diseases can greatly reduce 215 the number of PCR samples to be analyzed. Furthermore, Cohen and Kessel 216 reported high false-positive rates of RT-PCR testing for SARS-CoV-2 using clinical 217 samples. Overall, 336 of 10,538 negative samples (3.2%) were reported as positive. In contrast, <0.6–7.0% false-positive rates in external quality 218

of nucleic acids makes PCR-based assays highly sensitive but highly vulnerable
to minute levels of sample contamination which can produce false-positive results
indistinguishable from true-positive results [16]. The same pitfall may be found in
Loop-Mediated Isothermal Amplification (LAMP) method. We propose that

219

12

assessments of RNA virus assays were reported for influenza A. The amplification

224 macroscopic immunochromatographic-negative and PCR- or LAMP-positive 225 cases should be compared with highly sensitive immunochromatographic data 226 such as that obtained by INSM as well as clinical data to reduce false-positive 227 cases.

228 Although ImageJ/Fiji is useful software, it should be further developed to increase 229 its reliability. The development of an automated GNP counting system to replace 230 manual counting using deep learning is being evaluated by our team. Furthermore, 231 application automated clinical of using an inexpensive SEM for immunochromatography in combination with INSM for SEM shows potential. 232 Among the commonly used micro/nano-particles in immunochromatography, 233 colloidal GNP is the most widely used [3]. GNP is safe and can be easily 234 conjugated with biomolecules that retain their biochemical activity upon binding. 235 236 Therefore, developing new GNP-based LFBs may be easier and faster than 237 developing micro/nano-materials and can be adapted quickly for new emerging 238 infections such as SARS-CoV-2 [17]. Investigation of INSM using smaller GNPs is 239 currently underway. INSM is applicable to all LFBs, particularly in emergency tests to evaluate troponin, brain natriuretic peptide, and procalcitonin as measured by 240 241 immunochromatography.

Diagnosis using the INSM shows high sensitivity, as it allows for direct particle
observation. Our results indicate that INSM can be used for automated quantitative
measurement in any immunochromatographic tests including recently developed
SARS-CoV-2 antigen or IgM/IgG antibodies tests against SARS-CoV-2. This
method can be used to promptly diagnose new emerging infections including those
in livestock and promote innovations in assays using LFBs.

248

### 249 Acknowledgments

250 The authors thank Noriko Aoki (TAUNS Laboratories, Inc.) for providing rRT-PCR 251 data on influenza A and Takafumi Miwa and Takumi Tandou (Hitachi, Ltd. 252 Research & Development Group Nano-process Research Department) for 253 advising on SEM. We also thank the clinical laboratory center of Hamamatsu 254 University School of Medicine, University Hospital for providing influenza immunochromatography test strips after routine examinations. This work was 255 supported by JST START (grant number 714 [to H.K.]), JSPS KAKENHI (grant 256 numbers JP17K08784 [to H.K.] and JP18H01869 [to T.H.]), and AMED (grant 257 258 number A508 [to H.K.]).

259

## 260 **Competing interests**

261 The authors declare no competing interests.

#### References 262

263	[1]	Swerdlow DL, Finelli L. Preparation for possible sustained transmission of 2019
264		novel coronavirus: lessons from previous epidemics. JAMA. 2020;323: 1129-1130.
265	[2]	Ravina R, Dalal A, Mohan H, Prasad M, Pundir CS. Detection methods for
266		influenza A H1N1 virus with special reference to biosensors: a review. Biosci Rep.
267		2020;40.
268	[3]	Huang Y, Xu T, Wang W, Wen Y, Li K, Qian L, et al. Lateral flow biosensors based
269		on the use of micro- and nanomaterials: a review on recent developments.
270		Mikrochim Acta. 2019;187: 70.
271	[4]	Urusov AE, Zherdev AV, Dzantiev BB. Towards lateral flow quantitative assays:
272		detection approaches. Biosensors (Basel). 2019;9.
273	[5]	Takaku Y, Suzuki H, Ohta I, Ishii D, Muranaka Y, Shimomura M, et al. A thin
274		polymer membrane, nano-suit, enhancing survival across the continuum between
275		air and high vacuum. Proc Natl Acad Sci USA. 2013;110: 7631-7635.
276	[6]	Kawasaki H, Itoh T, Takaku Y, Suzuki H, Kosugi I, Meguro S, et al. The NanoSuit
277		method: a novel histological approach for examining paraffin sections in a
278		nondestructive manner by correlative light and electron microscopy. Lab Invest
279		2020;100: 161-173.
280	[7]	de-Paris F, Beck C, Machado ABMP, Paiva RM, da Silva Menezes D, de Souza
281		Nunes L, et al. Optimization of one-step duplex real-time RT-PCR for detection of

- influenza and respiratory syncytial virus in nasopharyngeal aspirates. J Virol
  Methods. 2012;186: 189-192.
- 284 [8] CDC. Division CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel
- 285 (CDC Flu rRT-PCR Dx Panel). 2014. Available from:
- 286 https://journals.plos.org/plosone/article/file?type=supplementary&id=info:doi/10.1
- 287 <u>371/journal.pone.0201248.s007</u>.
- 288 [9] WHO Collaborating Centre for Influenza, GA. CDC protocol of realtime RTPCR for
- 289 influenza A (H1N1) 2009. Available from:
- 290 https://www.who.int/csr/resources/publications/swineflu/realtimeptpcr/en/.
- 291 [10] O'Brien J, Hayder H, Peng C. Automated quantification and analysis of cell
  292 counting procedures using ImageJ plugins. J Vis Exp. 2016;17: 54719.
- 293 [11] Vemula SV, Zhao J, Liu J, Wang X, Biswas S, Hewlett I. Current approaches for
- diagnosis of influenza virus infections in humans. Viruses. 2016;8: 96.
- 295 [12] Yu ST, Bui CT, Kim DTH, Ngyuen AVT, Trinh TTT, Yeo SJ. Clinical evaluation of
- 296 rapid fluorescent diagnostic immunochromatographic test for influenza A virus
- 297 (H1N1). Sci Rep. 2018;8: 13468.
- 298 [13] Mitamura K, Zhimizu H, Yamazaki M, Ichikawa M, Nagai K, Katada J, et al. Clinical
- 299 evaluation of highly sensitive silver amplification immunochromatography systems
- 300 for rapid diagnosis of influenza. J Virol Methods. 2013;194: 123-128.

301	[14]	Nguyen AVT, Dao TD, Trinh TTT, Choi DY, Yu ST, Park H, et al. Sensitive
302		detection of influenza a virus based on a CdSe/CdS/ZnS quantum dot-linked rapid
303		fluorescent immunochromatographic test. Biosens Bioelectron. 2020;155: 112090.
304	[15]	Oh E, Liu R, Nel A, Gemill KB, Bilal M, Cohen Y, et al. Meta-analysis of cellular
305		toxicity for cadmium-containing quantum dots. Nat Nanotechnol. 2016;11: 479-486.
306	[16]	Cohen AN, Kessel B. False positives in reverse transcription PCR testing for
307		SARS-CoV-2. medRxiv. 2020.
308	[17]	Sheridan C. Fast, portable tests come online to curb coronavirus pandemic. Nat

309 Biotechnol. 2020;38: 515-518.



**Figure 1.** Sensitivity and specificity of immunochromatography using the NanoSuit<sup>®</sup> method. (*A*) Kit representation showing test and control lines. (*B*) Schematic diagram of the gold/platinum (Au/Pt)-Ab conjugate-linked rapid immunochromatographic kit. The immune-complex reacted with the anti-influenza A nucleoprotein (NP) at the test line and anti-mouse IgG at the control-line (top, middle). A NanoSuit<sup>®</sup> thin layer was formed after NanoSuit<sup>®</sup> treatment (bottom).

- 318 (C) Kit placement in the SEM chamber. (D) Determination of the observation
- 319 positions. Six fields were randomly selected in the test line and background areas.



321

Figure 2. (*A*, *B*) Images of cellulose and Au/Pt-labeled immunocomplex with immobilized antibody without (*A*) and with NanoSuit treatment (*B*). Scale bars in (*A*) and (*B*) = 15  $\mu$ m. Inset is magnified image. Scale bars 600 nm.



326

Figure 3. Comparison of SEM images of test lines and of background. (*A*, *D*) images of "macroscopic diagnosis-positive" test-line. (*B*, *E*) Images of "macroscopic diagnosis-negative" and "EM diagnosis-positive" test-line. (*C*, *F*) Images of "background". White arrows indicate representative Au/Pt particles. Scale bars in (*A*, *B*, *C*) = 30 µm and (*D*, *E*, *F*) = 3 µm.



Figure 4. Scatter plot of Ct and particle counts/field. Blue dot represents triplepositive ("macroscopic diagnosis-positive" and "EM diagnosis-positive" and "PCR diagnosis-positive"). Red dot represents double-positive ("EM diagnosis-positive" and "PCR diagnosis-positive"). Green dot represents single-positive ("PCR diagnosis-positive"). Blue dot line is approximate curve. Vertical axis: particle counts (log10)/field. Horizontal axis: Ct of influenza A.

Influenza A	Ct	Macroscopic diagnosis		Electron microscopic diagnosis	
rRT-PCR		Sensitivity	Specificity	Sensitivity	Specificity
Positive	14.0≤Ct<22.0	100% (3/3)		100% (3/3)	
(n=31)	22.0≤Ct<30.0	95.2% (20/21)		100% (21/21)	
	30.0≤Ct≤38.0	14.3% (1/7)		71.4% (5/7)	
	14.0≤Ct≤38.0	77.4% (24/31)		93.5% (29/31)	
Negative	Ct>38.0		100% (166/166)		100% (166/166)
(n=166)					

Table 1. Clinical diagnostic performance of EM assay. Thirty-one influenza A-rRTPCR-positive samples were used to determine the sensitivity of the assays, and
166 influenza rRT-PCR-negative samples were used to determine the specificity
of the assays.

		Macroscopic diagnosis			Electron microscopic diagnosis		
		positive	negative	Row Marginal	positive	negative	Row Marginal
Influenza A	Positive	24	7	31	29	2	31
rRT-PCR	Negative	0	166	166	0	166	166
Column Marginal		24	172	197	29	168	197
% Agreement(kappa)		0	.96: 24+166/197 0.99: 29+166/197		197		

- **Table 2.** Comparison of EM diagnosis with rRT-PCR and macroscopic diagnosis
- by immunochromatography.

350

# 351 Supplemental Figure 1.



- 353 (A) Immunochromatography diagnosis kit for IgM antibody against SARS-CoV-2.
- 354 (B) Background image. (C) Multiple gold nanoparticles (GNPs) (approximately 25-

- 355 nm diameter) of the control-line on cellulose. White arrows indicate representative
- 356 GNPs. Scale bars in (**B**) and (**C**) = 600 nm.



358 Supplemental Figure 2. Comparison of macroscopic, electron microscopic (EM)
359 and rRT-PCR influenza A diagnoses. (A) rRT-PCR amplification curve for

- influenza A. (**B**) Standard curve for rRT-PCR of influenza A. (**C**) Relationship
- 361 between cycle threshold (Ct) and sample copy numbers/reaction.

# 363 Supplemental data



364

365 Comparison of among macroscopic diagnosis, EM diagnosis and rRT-PCR

366 diagnosis. BG: Background, TL: Test Line



# **(**]









# Scatter plot of Ct and particle counts/field Macroscopic diagnosis positive + $y = 0.0001x^4 - 0.0105x^3 + 0.382x^2 - 5.8953x + 36.098$ EM diagnosis positive $R^2 = 0.7827$ +PCR positive EM diagnosis positive PCR positive PCR positive \*\*\*\*\*\*\* (Ct)30 34 38



Influenza A	Ct	Macroscopic diagnosis		Electron microscopic diagnosis	
rRT-PCR		Sensitivity	Specificity	Sensitivity	Specificity
Positive	$14.0 \le Ct < 22.0$	100% (3/3)		100% (3/3)	
(n=31)	22.0≤Ct<30.0	95.2% (20/21)		100% (21/21)	
	30.0≤Ct≤38.0	14.3% (1/7)		71.4% (5/7)	
	14.0≤Ct≤38.0	77.4% (24/31)		93.5% (29/31)	
Negative	Ct>38.0		100% (166/166)		100% (166/166)
(n=166)					

	Macroscopic dia		
		positive	n
Influenza A	Positive	24	7
rRT-PCR	Negative	0	1
Column Margi	24	1	
% Agreement(	0	.96	

agnosis		Electron microscopic diagnosis			
egative	Row Marginal	positive	negative	Row Marginal	
	31	29	2	31	
66	166	0	166	166	
72 197		29	168	197	
: 24+166/19'	7	0.99: 29+166/197			